- In September 2024, Sanofi and Regeneron announced plans to seek regulatory approval for Dupixent in the treatment of bullous pemphigoid following positive results from a Phase 3 clinical trial. The companies’ blockbuster anti-inflammatory biologic continues to gain momentum. On the same day, they shared promising data from a study on chronic spontaneous urticaria (CSU) and a new analysis of results in chronic obstructive pulmonary disease (COPD), the pivotal findings in the rare skin condition bullous pemphigoid (BP) pave the way for another regulatory submission
